Department of Urinary Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China.
Tissue Bank, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China.
Neural Regen Res. 2013 Sep 15;8(26):2468-77. doi: 10.3969/j.issn.1673-5374.2013.26.008.
To evaluate the association of X-ray cross-complementing group 1 (XRCC1) Arg399Gln, Arg194Trp and Arg280His polymorphisms with the risk of glioma.
A systematic literature search of papers published from January 2000 to August 2012 in PubMed, Embase, China National Knowledge Infrastructure database, and Wanfang database was performed. The key words used were "glioma", "polymorphism", and "XRCC1 or X-ray repair cross-complementing group 1". References cited in the retrieved articles were screened manually to identify additional eligible studies.
STUDIES WERE IDENTIFIED ACCORDING TO THE FOLLOWING INCLUSION CRITERIA: case-control design was based on unrelated individuals; and genotype frequency was available to estimate an odds ratio (OR) and 95% confidence interval (CI). Meta-analysis was performed for the selected studies after strict screening. Dominant and recessive genetic models were used and the relationship between homozygous mutant genotype frequencies and mutant gene frequency and glioma incidence was investigated. We chose the fixed or random effect model according to the heterogeneity to calculate OR and 95%CI, and sensitivity analyses were conducted. Publication bias was examined using the inverted funnel plot and the Egger's test using Stata 12.0 software.
Association of XRCC1 Arg399Gln, Arg194Trp, and Arg280His polymorphisms with the risk of glioma, and subgroup analyses were performed according to different ethnicities of the subjects.
Twelve articles were included in the meta-analysis. Eleven of the articles were concerned with the Arg399Gln polymorphism and glioma onset risk. Significantly increased glioma risks were found only in the dominant model (Gln/Gln + Gln/Arg versus Arg/Arg: OR = 1.26, 95%CI = 1.03-1.54, P = 0.02). In the subgroup analysis by ethnicity, significantly increased risk was found in Asian subjects in the recessive (OR = 1.46, 95%CI = 1.04-2.45, P = 0.03) and dominant models (OR = 1.40, 95%CI = 1.10-1.78, P = 0.007), and homozygote contrast (OR = 1.69, 95%CI = 1.17-2.45, P = 0.005), but not in Caucasian subjects. For association of the Arg194Trp (eight studies) and Arg280His (four studies) polymorphisms with glioma risk, the meta-analysis did not reveal a significant effect in the allele contrast, the recessive genetic model, the dominant genetic model, or homozygote contrast.
The XRCC1 Arg399Gln polymorphism may be a biomarker of glioma susceptibility, especially in Asian populations. The Arg194Trp and Arg280His polymorphisms were not associated with overall glioma risk.
评估 X 射线修复交叉互补基因 1（XRCC1）Arg399Gln、Arg194Trp 和 Arg280His 多态性与神经胶质瘤风险的关联。
系统检索了 2000 年 1 月至 2012 年 8 月期间在 PubMed、Embase、中国国家知识基础设施数据库和万方数据库中发表的文献，关键词为“神经胶质瘤”、“多态性”和“XRCC1 或 X 射线修复交叉互补组 1”。从检索到的文章中手动筛选参考文献，以确定其他合格的研究。
根据以下纳入标准确定研究：病例对照设计基于无关个体；并且基因型频率可用于估计比值比（OR）和 95%置信区间（CI）。经过严格筛选后，对选定的研究进行了荟萃分析。使用显性和隐性遗传模型，研究了纯合突变基因型频率与突变基因频率与神经胶质瘤发病的关系。我们根据异质性选择固定或随机效应模型来计算 OR 和 95%CI，并进行敏感性分析。使用 Stata 12.0 软件中的倒置漏斗图和 Egger 检验来检查发表偏倚。
XRCC1 Arg399Gln、Arg194Trp 和 Arg280His 多态性与神经胶质瘤风险的关联，并根据研究对象的不同种族进行亚组分析。
荟萃分析纳入了 12 篇文章。其中 11 篇文章研究了 Arg399Gln 多态性与神经胶质瘤发病风险的关系。仅在显性模型中发现神经胶质瘤风险显著增加（Gln/Gln+Gln/Arg 与 Arg/Arg：OR=1.26，95%CI=1.03-1.54，P=0.02）。在按种族进行的亚组分析中，在亚洲人群中，隐性（OR=1.46，95%CI=1.04-2.45，P=0.03）和显性模型（OR=1.40，95%CI=1.10-1.78，P=0.007）以及同型对照（OR=1.69，95%CI=1.17-2.45，P=0.005）中发现了显著的风险增加，但在高加索人群中没有发现。对于 Arg194Trp（8 项研究）和 Arg280His（4 项研究）多态性与神经胶质瘤风险的关联，荟萃分析未发现等位基因对照、隐性遗传模型、显性遗传模型或同型对照中存在显著影响。
XRCC1 Arg399Gln 多态性可能是神经胶质瘤易感性的生物标志物，尤其是在亚洲人群中。Arg194Trp 和 Arg280His 多态性与总体神经胶质瘤风险无关。
Zotero 插件
